Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects
NCT01216046 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48
Last updated 2012-01-18
Summary
The purpose of this study is to assess the pharmacokinetics and safety of VX-809 and VX-770 alone and in combination in healthy subjects.
Conditions
Interventions
- DRUG
-
VX-809
capsule, taken once daily
- DRUG
-
VX-770
tablet, taken once every 12 hours
- DRUG
-
VX-809 placebo
capsule, taken once daily
- DRUG
-
VX-770 placebo
tablet, taken once every 12 hours
Sponsors & Collaborators
-
Vertex Pharmaceuticals Incorporated
lead INDUSTRY
Principal Investigators
-
Laurent Vernillet, PharmD, PhD, FCP · Vertex Pharmaceuticals Incorporated
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2010-10-31
- Primary Completion
- 2011-05-31
- Completion
- 2011-05-31
Countries
- United States
Study Locations
More Related Trials
-
A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects
NCT03486236 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis
NCT03912233 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis
NCT03029455 ·Status: COMPLETED ·Phase: PHASE1
-
Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation
NCT01225211 ·Status: COMPLETED ·Phase: PHASE2
-
Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770
NCT01060566 ·Status: COMPLETED ·Phase: PHASE1
-
Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation
NCT01531673 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis
NCT03227471 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of VX-770 and Rifampin in Healthy Male Subjects
NCT01018368 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis
NCT03911713 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
NCT06154447 ·Status: RECRUITING ·Phase: PHASE1
-
Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion
NCT02070744 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation
NCT02516410 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis
NCT02951182 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)
NCT05033080 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
NCT05668741 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation
NCT02709109 ·Status: COMPLETED ·Phase: PHASE2
-
Rollover Study of VX-770 in Cystic Fibrosis Subjects
NCT01117012 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Evaluating the Long-term Safety of VX-445 Combination Therapy
NCT04043806 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
NCT03525444 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation
NCT01262352 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation
NCT02392234 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation
NCT01161537 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation
NCT05076149 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
NCT05444257 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor
NCT02347657 ·Status: COMPLETED ·Phase: PHASE3